Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma

International Journal of Cancer

Volumn 71, Issue 3, 1997, Pages 476-482

  Leong, Clement C ^a   Marley, Julia V ^a   Loh, Suzanne ^a   Milech, Nadia ^a   Robinson, Bruce W S ^b   Garlepp, Michael J ^a,b  

^a PATHWEST LABORATORY MEDICINE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CYTOTOXIC T LYMPHOCYTE; GENETIC HETEROGENEITY; GENETIC TRANSFECTION; IMMUNOGENICITY; IMMUNOMODULATION; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; ASBESTOS; CELL DIVISION; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; LYMPHOCYTE DEPLETION; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MICE; RECOMBINANT PROTEINS; SPLEEN; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0030916031     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970502)71:3<476::AID-IJC28>3.0.CO;2-C     Document Type: Article

References (22)

1. ALLISON, J.P., HURWITZ, A.A. and LEACH, D.R., Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr. Opinion Immunol., 7, 682-686 (1995).
2. CHEN, L., MCGOWAN, P., ASHE, S., JOHNSTON, J., LI, Y., HELLSTRÖM, I. and HELLSTRÖM, K.E., Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity, J. exp. Med., 179, 523-532 (1994).
3. COBBOLD, S.P., JAYASURIYA, A., NASH, A., PROPERO, T.D. and WALDMAN, H., Therapy with monoclonal antibodies by elimination of T cell subsets in vivo. Nature (Lond.), 312, 548-551 (1984).
4. DAVIS, M.R., MANNING, L.S., WHITAKER, D., GARLEPP, M.J. and ROBINSON, B.W.S., Establishment of a murine model of malignant mesothelioma. Int. J. Cancer 52, 881-886 (1992).
5. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D. and MULLIGAN, R.C., Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific and long-lasting antitumor immunity. Proc. nat. Acad. Sci. (Wash.), 90, 3539-3543 (1993).
6. FREEMAN, G.J. and 14 OTHERS, Murine B7-2, an alternative CTLA4 counter-receptor that co-stimulates T cell proliferation and interleukin-2 production. J. exp. Med., 178, 2185-2192 (1993).
7. FREEMAN, G.J., BOUSSIOTIS, V.A., ANUMANTHAN, A., BERNSTEIN, G.M., KE, X.Y., RENNERT, P.D., GRAY, G.S., GRIBBEN, J.G. and NADLER, L.M., B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. lmmunity, 2, 523-532 (1995).
8. + T lymphocytes in the P815 tumor system in vitro. J. Immunol., 156, 465-472 (1996).
9. HODGE, J.W., ABRAMS, S., SCHLOM, J. and KANTOR, J.A., Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 and B7-2 costimulatory molecules. Cancer Res., 54, 5552-5555 (1994).
10. JUNE, C.H., BLUESTONE, J.A., NADLER, L.M. and THOMPSON, C.B., The B7 and CD28 receptor families. Immunol. Today, 15, 321-332 (1994).
11. KUCHROO, V.K., DAS, M.P., BROWN, J.A., RANGER, A.M., ZAMVIL, S.S., SOBEL, R.A., WEINER, H.L., NABAVI, N. and GLIMCHER, L.H., B7-1 and B7-2 costimulatory molecules activate differentially the TH1/TH2 developmental pathways: application to autoimmune disease therapy. Cell. 80, 707-718 (1995).
12. LEACH, D.R., KRUMMEL, M.F. and ALLISON, J.P., Enhancement of antitumour immunity by CTLA-4 blockade. Science, 271, 1734-1737 (1996).
13. LENSCHOW, D.J., WALUNAS, T.L. and BLUESTONE, J.A., CD28/B7 system of T cell costimulation. Ann. Rev. Immunol., 14, 233-258 (1996).
14. LEONG, C., MARLEY, J., LOH, S., ROBINSON, B. and GARLEPP, M., Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma coll line requires expression of B7-1 and the capacity to upregulate class 11 major histocompatibility complex expression. Cancer Gene Therapy, 3, 321-330 (1996).
15. LINSLEY, P.S., GREENE, J.L., BRADY, W., BAJORATH, J., LEDBETTER, J.A. and PEACH, R., Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity, 1, 793-801 (1994).
16. MANNING, L.S., WHITAKER, D., MURCH, A.R., GARLEPP, M.J., DAVIS, M.R., MUSK, A.W. and ROBINSON, B.W.S., Establishment and characterisation of five human malignant mesothelioma cell lines derived from pleural effusions. Int. J. Cancer, 47, 285-290 (1991).
17. MATULONIS, U., DOSIOU, C., FREEMAN, G., LAMONT, C., MAUCH, P., NADLER, L.M. and GRIFFIN, J.D., B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukaemia immunity: further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol., 156, 1126-1131 (1996).
18. PARDOLL, D.M., Paracrine cytokine adjuvants in cancer immunotherapy. Ann. Rev. Immunol., 13, 399-416 (1995).
19. PARDOLL, D.M., Releasing the brakes on antitumour immune response. Science, 271, 1691 (1996).
20. RAMARATHINAM, L., CASTLE, M., WU, Y. and LIU, Y., T cell costimulation by B7/BB1 induces CDS T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment and effector function of anti-tumor T cells. J. exp. Med., 179, 1205-1214 (1994).
21. ROBINSON, B.W.S., DAVIDSON, J.A. and GARLEPP, M.J., The immunology and immunopathology of malignant mesothelioma. In: R.L. Kradin and B.W.S. Robinson (eds.). Immunopathology of lung disease, pp. 491-514, Butterworth-Heinemann, Boston (1996).
22. YANG, G., HELLSTRÖM, K.E., HELLSTRÖM, I. and CHEN, L., Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol., 154, 2794-2800 (1995).